SCHEMBL14476734

SCHEMBL14476734

CC(C)c1nnc(CO)n1Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 1/20 0.41
▸ PLA2G7 Q13093 3/20 0.39
▸ CHKA P35790 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ CLK2 P49760 1/20 0.39
▸ GSK3A P49840 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ PIK3C3 Q8NEB9 1/20 0.39
▸ CDK19 Q9BWU1 1/20 0.39
▸ LATS2 Q9NRM7 1/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ CSNK1G3 Q9Y6M4 1/20 0.39
▸ ALOX5AP P20292 1/20 0.39
▸ EPHB4 P54760 2/20 0.38
▸ TEK Q02763 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14476267 0.81 PPARG (0.41) CHKACYP2D6CYP2C9CCNCCYP2C19
SCHEMBL14476565 0.78 ALOX5AP (0.40) CHKACYP2D6CYP2C9CCNCCYP2C19
SCHEMBL14476842 0.74 CCR9 (0.42) P2RX3CHKACYP2D6CYP2C9CCNC
SCHEMBL14476728 0.74 PDE6D (0.44) PDE6DL3MBTL1
SCHEMBL14476729 0.72 KIF11 (0.43) PDE6DL3MBTL1
SCHEMBL14476623 0.72 KDM4E (0.39) CYP2D6CYP2C9CCNCCYP2C19CDK8
SCHEMBL14476260 0.71 P2RX7 (0.49) CHKAEPHB4TEKHDAC6
SCHEMBL14476560 0.70 AGTR1 (0.42) PLA2G7CHKACYP2D6CYP2C9CCNC
SCHEMBL15653992 0.69 CCR9 (0.56) CCR9
SCHEMBL14476621 0.69 CCR9 (0.42) P2RX3CHKAALOX5APEPHB4TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 — — US disclosed
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2014-06-19 — — US disclosed
EP-2725024-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2014-04-30 — — EP disclosed
WO-2013000108-A1 AZOLE HETEROCYLIC COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 中国科学院上海药物研究所 (CN) 2013-01-03 — — WO disclosed
WO-2013000267-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE 中国科学院上海药物研究所 (CN) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171431-A1 AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE PLA2G5, LTA4H, PLA2G4A P2RX3 801/4885PLA2G7 10/4885CHKA 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback